A Study to to Determine the Impact of a Mobile Health Application on Rheumatoid Arthritis Shared Decision Making


About this study

The primary objective of this study is to determine the impact of ArthritisPower™ integration into the clinical evaluation of patients with RA on the primary endpoint of clinical improvement as defined by the continuous change in the Clinical Disease Activity Index.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years.
  • Fulfillment of the ACR/EULAR 2010 classification criteria for RA.
  • Moderate or high disease activity, according to CDAI ≥ 10, at the baseline visit.
  • Intent to modify treatment with oral glucocorticoids or DMARDs (i.e., starting prednisone, changing the dose of prednisone, adding a DMARD, switching to a new DMARD, or changing DMARD dosage) by the patient and HCP.

Exclusion Criteria:

  • Current or previous use of Arthritis Power™ by the patient.
  • Lack of access to an ArthritisPower™ compatible device (e.g., smartphone, tablet, or computer)
  • Inability or unwillingness to participate with using the ArthritisPower™ app for this study.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

John Davis, M.D.

Closed for enrollment

Contact information:

Kathleen McCarthy-Fruin M.S.



More information


Publications are currently not available

Mayo Clinic Footer